What type of study is this?

September 5, 2025Open Access

Supplementary Figure 4 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

View Full Paper

Ask AI

Bookmark

CAR T cells demonstrated cytolytic activity in controlling myeloma even with limited BCMA expression, highlighting therapeutic potential.
The analysis revealed effective targeting of CD229 antigen by CAR T cell therapy, showing promise in multiple myeloma treatment.
Co-culture experiments with K562 cell lines over 24 hours confirmed the specific activity of CAR T cells against CD229, supporting further research.
This research suggests dual targeting of BCMA and CD229 may improve outcomes in myeloma, calling for further clinical validation.

Observational analysis shows CAR T cells effectively control myeloma in cell lines, indicating dual targeting may enhance treatment.

Specific cytolytic activity of CAR T cells co-culture during 24h with K562 cell lines with different expression of CD229 antigen

No takes yet. Share an insight, caveat, or question.

Rodríguez‐Lobato et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis shows CAR T cells effectively control myeloma in cell lines, indicating dual targeting may enhance treatment.

Specific cytolytic activity of CAR T cells co-culture during 24h with K562 cell lines with different expression of CD229 antigen